| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.9 |